BRENDA PRIMERO: Open Payments
NPI 1831613025 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,389 in 69 payments from 13 companies in 2025. Trend: 2023 $2,321 · 2024 $1,856 · 2025 $1,389
Food & beverage: $1,389
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $247 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $220 |
| ABBVIE INC. | 10 | $204 |
| Neurocrine BioSciences, Inc. | 7 | $185 |
| Janssen Pharmaceuticals, Inc | 7 | $152 |
| E.R. Squibb & Sons, L.L.C. | 10 | $149 |
| Alkermes, Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
Products named: CAPLYTA, VRAYLAR, REXULTI, INGREZZA, COBENFY, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across NV — which companies pay providers there.
